MARKET

TLSA

TLSA

Tiziana Life Sciences Ltd Com
NASDAQ
1.180
-0.080
-6.35%
Closed 19:31 04/10 EDT
OPEN
1.270
PREV CLOSE
1.260
HIGH
1.270
LOW
1.141
VOLUME
341.05K
TURNOVER
0
52 WEEK HIGH
2.600
52 WEEK LOW
0.7301
MARKET CAP
150.63M
P/E (TTM)
-10.3873
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at TLSA last week (0330-0403)?
Weekly Report · 6d ago
Tiziana Life Sciences Stock Jumps As Positive Preclinical Fuels Momentum
Benzinga · 04/01 17:10
Tiziana Life Sciences Reports Positive Preclinical Data for Nasal Anti-CD3 in Age-Related Cognitive Decline
TipRanks · 04/01 12:42
Tiziana says preclinical data show intranasal foralumab reverses brain aging, boosts cognition
Reuters · 04/01 11:00
Weekly Report: what happened at TLSA last week (0323-0327)?
Weekly Report · 03/30 09:40
12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga · 03/26 21:05
Weekly Report: what happened at TLSA last week (0316-0320)?
Weekly Report · 03/23 09:38
Tiziana Life Sciences Ltd. Director and 10% Owner Gabriele M. Cerrone Files Initial Beneficial Ownership Statement
Reuters · 03/19 01:18
More
About TLSA
Tiziana Life Sciences Ltd. is a United Kingdom-based clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The Company’s clinical pipeline includes drug assets for secondary progressive multiple sclerosis, Alzheimer’s, and ALS. Its lead immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer’s and other CNS indications. Its Anti-IL-6R mAb (TZLS-501), a fully human mAb, binds to both membrane-bound and soluble forms of IL-6R, an inflammatory cytokine driving chronic inflammation associated with autoimmune and cancer, reducing circulating levels of the IL-6 cytokine. Its oncology product candidate, Milciclib, is a combination therapy for the treatment of refractory solid tumors (being cancers which are non-responsive or become resistant to treatment), especially non-small cell lung cancer (NSCLC).

Webull offers Tiziana Life Sciences Ltd - ADR stock information, including NASDAQ: TLSA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TLSA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TLSA stock methods without spending real money on the virtual paper trading platform.